Zacks Investment Research upgraded shares of Cambrex (NYSE:CBM) from a sell rating to a hold rating in a research report released on Wednesday, April 11th.
According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “
Other equities analysts also recently issued research reports about the company. William Blair assumed coverage on Cambrex in a research report on Tuesday, January 16th. They set an outperform rating for the company. Longbow Research downgraded Cambrex from a buy rating to a neutral rating in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Cambrex presently has an average rating of Hold and an average price target of $60.00.
Cambrex (NYSE:CBM) last posted its quarterly earnings data on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.17. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The company had revenue of $182.28 million during the quarter, compared to analysts’ expectations of $181.39 million. During the same period last year, the firm earned $1.23 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. research analysts anticipate that Cambrex will post 2.81 earnings per share for the current year.
Institutional investors and hedge funds have recently modified their holdings of the business. Aperio Group LLC lifted its stake in shares of Cambrex by 10.5% during the fourth quarter. Aperio Group LLC now owns 9,759 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 927 shares in the last quarter. Stone Ridge Asset Management LLC acquired a new position in shares of Cambrex in the fourth quarter worth about $620,000. We Are One Seven LLC acquired a new position in shares of Cambrex in the fourth quarter worth about $320,000. JPMorgan Chase & Co. lifted its stake in shares of Cambrex by 117.0% in the third quarter. JPMorgan Chase & Co. now owns 231,931 shares of the biotechnology company’s stock worth $12,721,000 after acquiring an additional 125,062 shares in the last quarter. Finally, Teachers Advisors LLC lifted its stake in shares of Cambrex by 3.8% in the fourth quarter. Teachers Advisors LLC now owns 369,203 shares of the biotechnology company’s stock worth $17,722,000 after acquiring an additional 13,557 shares in the last quarter.
WARNING: This report was first reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://weekherald.com/2018/04/19/cambrex-cbm-upgraded-to-hold-at-zacks-investment-research.html.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.